Monoclonal antibodies have a track record in the effective treatment of autoimmune diseases including psoriasis, atopic dermatitis, systemic lupus, and multiple sclerosis. In general, autoimmune diseases involve dysregulation of multiple immune cell types that contribute to the overall pathology. Understanding of the acquisition of immune phenotypes and their interactions only becomes better in recent years. The phenotypes and interactions are complex and it is clear that multiple targeting is needed for many autoimmune diseases in order to achieve the next level of efficacy and disease control. For example, although the anti-IL-4Rα antibody dupilumab was approved for atopic dermatitis, only 35-40% of treated patients achieved clean or almost clean skin; the anti-Blys antibody belimumab was approved for lupus but the unmet needs remain high.Hongcheng is committed to the in-depth analysis of the biology of autoimmune diseases, and provides the best target for the development of the next generation of monoclonal antibodies or bispecific antibodies with superior efficacy.